It was also reported that survivin-2B expression was dominant in benign brain tumours in comparison with the malignant ones (Yamada et al, 2003), and that survivin-ΔEx3 expression was prominent in comparison with survivin-2B expression in survivin-expressing acute lymphocytic leukaemia (ALL) and chronic lymphocytic leukaemia (CLL) patient bone marrow samples (Nakagawa et al, 2004). This evidence concerns the gene BIRC5 and acute lymphoblastic leukemia.